



8 December 2022  
EMA/CVMP/QWP/339588/2005 – Rev 1  
Committee for Veterinary Medicinal Products (CVMP)

## Guideline on Parametric release

<b>Draft agreed by Quality Working party</b>	February 2006
<b>Draft agreed by Ad Hoc GMP Inspectors Working Party</b>	January 2006
<b>Adopted by CVMP for release for consultation</b>	15 March 2006
<b>End of consultation (deadline for comments)</b>	30 June 2006
<b>Agreed by Quality Working Party</b>	September 2006
<b>Adopted by CVMP</b>	12 October 2006
<b>Date for coming into effect</b>	1 January 2007
<b>Revision 1*</b>	
<b>Agreed by QWP</b>	23 November 2022
<b>Adopted by CVMP</b>	8 December 2022
<b>Date for coming into effect</b>	17 February 2023

\*The current revision consists of administrative changes made in order to align the guideline with Regulation (EU) 2019/6, as amended and to align with the current EMA template for Guidance. The references to the legislation applicable and other scientific guidelines have also been updated as appropriate. As no changes were made to the scientific content, no concept paper and no public consultation were deemed necessary.

<b>Keywords</b>	Parametric release
-----------------	--------------------



# Guideline on Parametric release

## Table of contents

<b>Executive summary .....</b>	<b>3</b>
<b>1. Introduction (background).....</b>	<b>3</b>
<b>2. Scope.....</b>	<b>3</b>
<b>3. Legal basis .....</b>	<b>3</b>
<b>4. Main Guideline text.....</b>	<b>4</b>
4.1. Parametric release.....	4
4.1.1. Parametric release and sterilisation.....	4
4.1.2. Process monitoring .....	4
4.2. Assessment of applications .....	4
4.3. Manufacturing process .....	5
4.3.1. General .....	5
4.3.2. Sterilisation process.....	6
<b>Definitions.....</b>	<b>7</b>
<b>References (Scientific and/or Legal) .....</b>	<b>7</b>

# Executive summary

This Guideline outlines the requirements for applications for veterinary medicinal products in which the use of parametric release is proposed and highlights the different requirements that have to be fulfilled in such an application and during the inspection, respectively.

## 1. Introduction (background)

A medicinal product must comply with the requirements stated in the authorised specifications for release and shelf life. Nevertheless, this does not mean that all tests in the specifications have to be carried out on the finished product before release (Ref. 1). The manufacturer may obtain assurance that the product is of stipulated quality and meets its specification through a system called parametric release. Parametric release is based on evidence of successful validation of the manufacturing process and review of the documentation on the additional process monitoring carried out during manufacture to support parametric release. Consequently, parametric release is used as an operational alternative to routine release testing of certain, specific parameters.

The European Pharmacopoeia refers to parametric release without making a distinction between human and veterinary medicinal products, for example, the monograph "Methods of preparation of sterile products" (Ref. 2). Furthermore, the scope of Annex 17 "Parametric release" of the EU GMP Guide (Ref. 3) also extends to both human and veterinary medicinal products.

This guideline parallels the current guidance on this topic for human medicinal products. It is intended to outline the requirements for applications that propose parametric release for finished veterinary medicinal products and it highlights the different requirements that have to be fulfilled in the application and during the inspection, respectively. It has therefore been developed jointly by the Joint CHMP/CVMP Quality Working Party and the Ad Hoc GMP Inspectors Group of the EMA.

## 2. Scope

The principle of parametric release may be applied during the stages of manufacture of different products resulting in the elimination of certain, specific tests of the finished product. Although this guideline focuses on the parametric release of products for which the sterility test is replaced, this is because more experience is available with such applications at the present time.

The scope of this guidance is restricted to veterinary medicinal products which are not biological medicinal products<sup>1</sup>.

It would be premature at the present time for this guideline to include reference to several current initiatives within the harmonisation process, and also the topical issue of process analytical technology (PAT). However it is acknowledged that a revision of this guidance (and the existing human guidance) will be required in the not-too-distant future once these issues have been elaborated and harmonised.

## 3. Legal basis

Annex II to Regulation (EU) 2019/6 as amended requires that specifications be established for the active substance and for the veterinary medicinal product. It further indicates that the tests performed routinely should be indicated. Hence, the concept of not testing every parameter at the time of release of a batch is introduced.

---

<sup>1</sup> Using the definition of a biological veterinary medicinal product given Regulation (EU) 2019/6.

## **4. Main Guideline text**

### **4.1. Parametric release**

#### **4.1.1. Parametric release and sterilisation**

Parametric release is referred to in the monograph “Methods of preparation of sterile products” in the European Pharmacopoeia (Ref. 2). This states “When a fully validated terminal sterilisation method by steam, dry heat or ionising radiation is used, parametric release, that is the release of a batch of sterilised items based on process data rather than on the basis of submitting a sample of the items to sterility testing, may be carried out, subject to the approval of the competent authority.”

Parametric release can only be applied to products terminally sterilised in their final containers. The statistical limitations of the sterility test in predicting sterility assurance are well known. Approval for parametric release eliminates the requirement for a finished product sterility test as a condition for batch release. The release of each batch is dependent on the successful demonstration that pre-determined, validated sterilising conditions have been achieved throughout the load. All relevant sterilisation parameters e.g. temperature, pressure and time, must be accurately controlled and measured.

#### **4.1.2. Process monitoring**

Process monitoring may be applied to other manufacturing processes, such as tableting, on the basis of manufacturing history and appropriate testing at various stages in the process. Some parameters are usually checked routinely at defined intervals regardless of the design of the manufacturing process of a tablet. Tablet weight, crushing strength and disintegration are such examples. The results of a comprehensive set of in-process tests and controls in these cases may constitute sufficient grounds for batch release and provide greater assurance of the finished tablet meeting certain criteria in the specification without the tests being repeated on a sample of the finished product.

Other examples are the use of process analytical technology test methods, such as vibrational spectroscopy techniques like near infrared spectroscopy (NIR) and Raman spectroscopy, usually used in combination with multivariate analysis. Spectral data monitored on-line controlling content of active substance, polymorphism, water content, blending homogeneity, particle/powder properties or film thickness could thereby replace end-product testing such as uniformity of content, tablet strength and drug dissolution.

When parametric release is applied, the attribute that is indirectly controlled (e.g. sterility, uniformity of dosage unit) together with a reference to the associated test procedure, should still be included in the specifications. However, the relationship between end-product testing and process monitoring, including acceptance criteria, should be justified.

### **4.2. Assessment of applications**

In general the documentation submitted for a new marketing authorisation or a variation should contain only those elements of the quality assurance that are specific for the veterinary medicinal product. The quality assurance of elements not specific to the product falls within the field of GMP.

It is likely that in many cases, parametric release will be introduced following a variation requiring assessment to an existing marketing authorisation when more experience has been gained with the manufacture of the product.

Parametric release may however also be considered suitable where a new product is very similar to an existing product and test data for the closely related product are considered relevant. Similarly, if the product is already registered as a human medicinal product (inside or outside the EU) or as a veterinary medicinal product outside the EU, in these cases a significant body of manufacturing/testing data may be available for the relevant product produced at the relevant manufacturing site. However, if manufacture of the product takes place in a country which is outside of the EU and is not an MRA partner, then due account should be taken of the normal obligations for retesting of products on entry into the EU. The only exception to this would be in connection with sterility testing. It is accepted that if parametric release has been agreed in connection with sterility, then bearing in mind that sterility testing is statistically limited, this is not considered to be a necessary test on entry of a product into the EU and hence does not need to be performed.

The assessment of applications is made with close collaboration between assessors and inspectors as each has different tasks. The opinion of the inspector is obtained, which includes the evaluation of a risk analysis of the sterility assurance system where appropriate, and included in the overall assessment of the application. Approval as well as withdrawal of parametric release is at the discretion of the Competent Authority. A withdrawal may be based on the results of an inspection or on the receipt of other information.

With the exception of sterility testing an approval may also be qualified by requiring a running-in period of reduced confirmatory testing.

### **4.3. Manufacturing process**

#### **4.3.1. General**

For some dosage forms, the different stages of manufacturing process will be discrete, thus allowing sampling at critical parts of distinct stages of the process. For other dosage forms, the manufacturing process may be more or less continuous, necessitating a more integrated process monitoring. It is therefore not possible to specify in a guideline, specific details of how parametric release can be applied. This must be assessed in each individual case verifying that the requirements of appropriate Notes for Guidance are met.

The authorisation of the parametric release programme will be granted on the basis of an assessment of how well the manufacturing process concerned is founded. The demonstration of the robustness through to the final validation of the manufacturing process will therefore be assessed. Monitoring of critical parameters must be capable of demonstrating that pre-determined validated conditions have been achieved throughout the batch. In addition, evaluators will assess the choice and limits of the critical parameters in relation to their effect on the technical characteristics, stability and bioavailability of the product and its packaging. Methods of controlling critical parameters will also be assessed.

The application that proposes parametric release must be based on sufficient experience with the process, evaluation of the historical compliance to GMP as well as current compliance. The general basis upon which an authorisation may be granted should include documentation that shows:

- that the manufacturing process is validated adequately,
- that it is reliably controlled,
- the relationship between end-product testing and process monitoring, including justification of acceptance criteria
- that in-process requirements chosen for approval/rejection are decided on the basis of the acceptance criteria defined in the validation records,

- that clear, specified procedures are in place describing the reporting and actions to be taken on approval/rejection
- historical batch data.

GMP compliance will be covered during inspections. Routine inspections are carried out in accordance with the general procedures of the Competent Authority concerned. The basic EU –GMP Guide, Annex 1 on manufacture of sterile products, and other relevant annexes are used as the reference (Ref. 3). In connection with evaluation of applications for parametric release, pre-authorisation product specific inspections should normally be carried out. However, where the manufacturing site already has approval for parametric release for a very similar activity (i.e. product/process/test) an inspection will not be necessary. When an inspection is required the inspector will use the Annex 17 of the EU GMP Guide on parametric release as reference (Ref. 3) and focus the inspection on the accuracy of the process, the programmes for revalidation and change control. The in-process controls and procedures are checked to be in accordance with the process described in the application and with the assessment report as a reference. As regards sterile products, the inspector will on all inspections check that standard operating procedures for the various stages in the manufacturing process that are of significance for sterility are in place. In particular, the procedures for quality control of starting materials, packaging materials, process water and environmental monitoring are checked. Other aspects of importance are, for example, filtration procedures, equipment cleaning/sterilisation procedures, maximum holding times for bulk solutions, and quality of the cooling medium.

### **4.3.2. Sterilisation process**

The sterilisation process in an application for parametric release of sterility must be in accordance with the requirements of the European Pharmacopoeia. Consequently, parametric release can only be applied to products sterilised in their final containers by moist heat, dry heat or radiation (Ref. 2). The choice of a sterilisation process must be well founded and consider both the knowledge of the stability of the product under relevant conditions and the data gained in development studies where critical process parameters are identified.

#### **4.3.2.1. Sterilisation by heat**

A sterilisation process shall be validated in accordance with GMP guidelines. Qualification of equipment and validation of the process which is applied at a particular time, including heat distribution and heat penetration studies with a given, established load pattern are thus carried out so that heat equivalents can be calculated. The technical validation of a heat sterilisation method shall be complemented by a biological validation. Consideration shall be given to the level and heat resistance of bioburden. When the sterilisation process has been defined, its reproducibility shall be demonstrated. Compliance with specific GMP requirements as described in Annex 17 to the EU GMP Guide should also be demonstrated. An example of such a requirement is the segregation of non-sterile products from sterilised products.

An application for parametric release of sterility should be supported by:

- a description of the sterilisation process including type of cycle, load pattern, specifications for cycle parameters (time, temperature, pressure, F0 value) and chemical indicators (if applicable)
- specifications and methods/procedures applied for in-process controls e.g. pre-sterilisation bioburden, monitoring of cycle parameters and verification of load sterilisation

- a process validation report comprising heat distribution and heat penetration studies for at least three runs, and a microbiological qualification showing sufficient efficacy at the minimum level of the cycle including information on the biological indicators used (type, D-value, Z-value, stability), and bioburden characteristics (number, type, resistance) as applicable
- package integrity data (if applicable).

In general, no new documentation is required regarding the sterilisation process. Reference could, where applicable, be made to previously submitted data.

Once parametric release has been granted, decisions for release or rejection of a batch must be based on the approved specification. Such a decision cannot be overruled by the use of sterility tests.

#### **4.3.2.2. Sterilisation by radiation**

Parametric release can also be applied in the case of sterilisation by radiation. The minimum absorbed dose should generally be 25 kGy. Lower doses can be acceptable if justified by low, routinely checked, bioburden levels and adequate validation data (Refs. 4 & 5).

The same requirements regarding documentation as for sterilisation by heat must be met, where applicable. The documentation shall comply with the guidelines defined by the EU with regard to ionising radiation.

## **Definitions**

The definition of parametric release used in the document (and in the guideline for human products) is based on that proposed by the European Organisation for Quality, EOQ. Parametric release is a system of release that gives the assurance that the product is of the intended quality based on information collected during the manufacturing process and on the compliance with specific GMP requirements related to Parametric Release.

## **References (Scientific and/or Legal)**

1. Ph. Eur., current edition, General Statements
2. Ph. Eur., current edition, Methods of preparation of sterile products
3. The Rules Governing Medicinal Products in the European Union, Volume 4
4. Note for Guidance on The use of Ionising Radiation in the Manufacture of Medicinal Products (III/9109/90)
5. European Standard EN 552:1994, Sterilisation of medical devices – Validation and routine control of sterilisation by irradiation